|
IKNA | Ikena Oncology, Inc. |
|
|
IKNA | Ikena Oncology, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.61 |
| Leverage | 8.13% |
| Market Cap | $ 71.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -30.6m |
| Margin | -394.77% |
Ikena Oncology, Inc., a targeted oncology company, is focused on developing new cancer therapies that target key signaling pathways that drive cancer formation and spread. The company is headquartered in Boston, Massachusetts.